Description:
* "ICP Biotechnology Limited (BIO) listed on the New Zealand Exchange today, following the completion of the reverse takeover of publicly listed Australasian Property Holdings Group (APH).

Principal shareholders are Managing Director Dr Earl Stevens and his wife Tracey, with 39.8% of the company's equity. Other directors are Roger Gower (Chairman) and Alistair Ward.
ICPbio is part of the SciTec Index, which the NZX launched yesterday.

One of New Zealand's longest established biotechnology companies, ICPbio manufactures and markets products for use in animal reproduction, animal health care and the fine biochemicals field.

ICPbio's vision is set on becoming a leading global manufacturer of quality biological products for the biotechnology, animal and human pharmaceutical industries.
Nearly 100% of its products are exported, primarily to North America and Europe, with increasing amounts to Asia and South America."

Website: http://www.icpbio.com/

Recent announcements: click here

IPOs and Investment Opportunities

Not yet available

Gain access to professional equity research reports

Company balance date: 30 June

Trading over the last year

 

Supplementary Information

The ICPbio Advantage – Low Risk, High Return

ICP Biotechnology Limited (“ICPbio”) is a growing Auckland based biotechnology company. It is one of New Zealand’s longest established biotechnology companies and currently manufactures and markets products for use in animal reproduction, animal health care and the fine biochemicals field. The Group has an established reputation for providing innovative technical and commercial solutions for the pharmaceutical and animal health industries.  Over 95% of its products are exported, primarily to North America and Europe, with increasing amounts to Asia and South America.

ICPbio’s vision is to become a leading global manufacturer of quality biological products for the biotechnology, animal and human pharmaceutical industries.

ICPbio’s manufacturing processes add very high value to low-cost biological raw materials derived from the New Zealand Meat industry. It takes low-value agricultural by-products and turns it into a range of high-value raw materials (some in excess of $50,000 per kg) for the pharmaceutical and biotechnology industry, for vaccines, cell culture, designer drugs, and the like, but without the risk and large expenditure faced by its customers.

ICPbio’s New Zealand location provides it with real competitive advantages including:

·          Biological raw materials that are sourced from farmed animals and from the plentiful by-products of New Zealand’s extensive meat processing industry.

·          New Zealand’s international standing as one of the world’s environmentally cleanest, safest and secure countries free of animal and viral diseases of major economic significance.

The key point of difference between ICPbio and many other biotechnology companies is that its success is not dependent on discovering and exploiting novel intellectual property. The Group has an expanding range of products for customers including multinational biotechnology and pharmaceutical companies. ICPbio manufactures many of the media, serums and biochemicals these companies use to make, test, store or deliver their products, enabling the Group to make sales and generate profits regardless of the final outcome of the customer’s discovery process.

While we seek to publish all comments, any comments that are in bad taste, spurious or defamatory will not be published or will be sent back to the sender for editing. Comments can be submitted anonymously, please specify if you wish to remain anonymous. Submitting will take you back to the home page.